Motus readies for commercial launch of Pure-Vu, posts $5.2M net loss for Q1 — 3 insights

Motus GI released its first quarter 2019 financial results, posting a $6.3 million net loss, or a $0.29 loss per diluted share.

What you should know:

1. Motus has $15.3 million in cash and investments.

2. In the quarter, Motus submitted a 510(k) application for the second-generation Pure-Vu System. The new system improves system mobility and setup logistics.

3. Motus has several milestones it anticipates hitting in the coming quarter, including:

  • Announcing the full clinical results of its Reduce study at Digestive Disease Week 2019, May 18-21 in San Diego. In initially announced results, Pure-Vu showed a statistically significant improvement in bowel cleanliness from baseline in 45 patients.
  • Starting investigator-led studies centering on Pure-Vu's effectiveness for inpatient colonoscopy and high-risk outpatient colonoscopy populations
  • Expanding its field-based sales and U.S. clinical resources market.

For more on Motus' milestones, click here.

More articles on gastroenterology:
Where a Kansas ASC plans to invest for future growth: Q&A with Director Sonja Clapp
Orthopedist salaries, USPI revenue & more: 5 must-read articles for ASC administrators
5 key traits of effective ASC administrators

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers